UPLIZNA Offers gMG Patients Deep and Durable Symptom Control and Twice-Yearly Dosing*
First and Only CD19-Targeted B Cell Therapy Approved in anti-AChR and anti-MuSK Ab+ gMG
FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS| Amgen
UPLIZNA Offers gMG Patients Deep and Durable Symptom Control and Twice-Yearly Dosing*
First and Only CD19-Targeted B Cell Therapy Approved in anti-AChR and anti-MuSK Ab+ gMG